Tags

Type your tag names separated by a space and hit enter

Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Int J Mol Med. 2011 Dec; 28(6):985-91.IJ

Abstract

Trastuzumab has efficacy to improve the effect of cytotoxic drugs, such as paclitaxel and anthracyclin, against HER2-overexpressing breast cancer cells. Sodium butyrate (NaB), a histone deacetylase inhibitor, is known to have antitumoral properties. However, whether and how trastuzumab possesses the potential to synergize the anti-tumor effect of NaB on breast cancer cells is still equivocal. To elucidate whether combined treatment with NaB and trastuzumab exerts anti-tumor effects on a HER2-overexpressing breast cancer cell line, SKBR3 cells were treated with NaB alone or in combination with trastuzumab, and the effects on proliferation and cell cycle progression were analyzed. Combinatory treatment with NaB (4 mmol/l) and trastuzumab (20 µg/ml) significantly increased the growth-inhibitory effect on SKBR3 breast cancer cells, in comparison to NaB or trastuzumab treatment alone. The growth-inhibitory effect of the combination of NaB and trastuzumab was accompanied by elevated mRNA and protein levels of the cyclin-dependent kinase inhibitor p27Kip1. In contrast, this effect was absent in HER2-negative HCC1937 cells. In conclusion, trastuzumab significantly improved the antitumor effect of NaB on HER2-overexpressing breast cancer cell line in vitro.

Authors+Show Affiliations

Department of Medical Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21887460

Citation

Chen, Weiwei, et al. "Trastuzumab Enhances the Anti-tumor Effects of the Histone Deacetylase Inhibitor Sodium Butyrate On a HER2-overexpressing Breast Cancer Cell Line." International Journal of Molecular Medicine, vol. 28, no. 6, 2011, pp. 985-91.
Chen W, Wei F, Xu J, et al. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. Int J Mol Med. 2011;28(6):985-91.
Chen, W., Wei, F., Xu, J., Wang, Y., Chen, L., Wang, J., & Guan, X. (2011). Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. International Journal of Molecular Medicine, 28(6), 985-91. https://doi.org/10.3892/ijmm.2011.790
Chen W, et al. Trastuzumab Enhances the Anti-tumor Effects of the Histone Deacetylase Inhibitor Sodium Butyrate On a HER2-overexpressing Breast Cancer Cell Line. Int J Mol Med. 2011;28(6):985-91. PubMed PMID: 21887460.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. AU - Chen,Weiwei, AU - Wei,Feng, AU - Xu,Jing, AU - Wang,Yucai, AU - Chen,Longbang, AU - Wang,Jinghua, AU - Guan,Xiaoxiang, Y1 - 2011/09/01/ PY - 2011/06/14/received PY - 2011/08/09/accepted PY - 2011/9/3/entrez PY - 2011/9/3/pubmed PY - 2012/1/27/medline SP - 985 EP - 91 JF - International journal of molecular medicine JO - Int J Mol Med VL - 28 IS - 6 N2 - Trastuzumab has efficacy to improve the effect of cytotoxic drugs, such as paclitaxel and anthracyclin, against HER2-overexpressing breast cancer cells. Sodium butyrate (NaB), a histone deacetylase inhibitor, is known to have antitumoral properties. However, whether and how trastuzumab possesses the potential to synergize the anti-tumor effect of NaB on breast cancer cells is still equivocal. To elucidate whether combined treatment with NaB and trastuzumab exerts anti-tumor effects on a HER2-overexpressing breast cancer cell line, SKBR3 cells were treated with NaB alone or in combination with trastuzumab, and the effects on proliferation and cell cycle progression were analyzed. Combinatory treatment with NaB (4 mmol/l) and trastuzumab (20 µg/ml) significantly increased the growth-inhibitory effect on SKBR3 breast cancer cells, in comparison to NaB or trastuzumab treatment alone. The growth-inhibitory effect of the combination of NaB and trastuzumab was accompanied by elevated mRNA and protein levels of the cyclin-dependent kinase inhibitor p27Kip1. In contrast, this effect was absent in HER2-negative HCC1937 cells. In conclusion, trastuzumab significantly improved the antitumor effect of NaB on HER2-overexpressing breast cancer cell line in vitro. SN - 1791-244X UR - https://www.unboundmedicine.com/medline/citation/21887460/Trastuzumab_enhances_the_anti_tumor_effects_of_the_histone_deacetylase_inhibitor_sodium_butyrate_on_a_HER2_overexpressing_breast_cancer_cell_line_ DB - PRIME DP - Unbound Medicine ER -